These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9385549)

  • 1. Diverse binding site structures revealed in homology models of polyreactive immunoglobulins.
    Ramsland PA; Guddat LW; Edmundson AB; Raison RL
    J Comput Aided Mol Des; 1997 Sep; 11(5):453-61. PubMed ID: 9385549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural aspects of human IgM antibodies expressed in chronic B lymphocytic leukemia.
    Ramsland PA; Brock CR; Moses J; Robinson BG; Edmundson AB; Raison RL
    Immunotechnology; 1999 Mar; 4(3-4):217-29. PubMed ID: 10231091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
    Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
    J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational similarity and systematic displacement of complementarity determining region loops in high resolution antibody x-ray structures.
    Bajorath J; Harris L; Novotny J
    J Biol Chem; 1995 Sep; 270(38):22081-4. PubMed ID: 7673180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unusual human IgM antibody with a protruding HCDR3 and high avidity for its peptide ligands.
    Ramsland PA; Shan L; Moomaw CR; Slaughter CA; Fan Z; Guddat LW; Edmundson AB
    Mol Immunol; 2000 Apr; 37(6):295-310. PubMed ID: 11000403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model.
    Essen LO; Skerra A
    J Mol Biol; 1994 Apr; 238(2):226-44. PubMed ID: 8158652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region.
    Keck PC; Huston JS
    Biophys J; 1996 Oct; 71(4):2002-11. PubMed ID: 8889174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.
    Eigenbrot C; Randal M; Presta L; Carter P; Kossiakoff AA
    J Mol Biol; 1993 Feb; 229(4):969-95. PubMed ID: 8095303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia.
    Capello D; Guarini A; Berra E; Mauro FR; Rossi D; Ghia E; Cerri M; Logan J; Foà R; Gaidano G
    Leukemia; 2004 Dec; 18(12):1941-7. PubMed ID: 15483675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgM expressed by leukemic CD5(+) B cells binds mouse immunoglobulin light chain.
    Weston KM; Tangye SG; Dunn RD; Smith A; Morris MB; Raison RL
    J Mol Recognit; 2001; 14(4):245-53. PubMed ID: 11500971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural consequences of humanizing an antibody.
    Holmes MA; Foote J
    J Immunol; 1997 Mar; 158(5):2192-201. PubMed ID: 9036965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refined crystal structure of a recombinant immunoglobulin domain and a complementarity-determining region 1-grafted mutant.
    Steipe B; Plückthun A; Huber R
    J Mol Biol; 1992 Jun; 225(3):739-53. PubMed ID: 1602480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction.
    Zhu K; Day T; Warshaviak D; Murrett C; Friesner R; Pearlman D
    Proteins; 2014 Aug; 82(8):1646-55. PubMed ID: 24619874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
    Almog O; Benhar I; Vasmatzis G; Tordova M; Lee B; Pastan I; Gilliland GL
    Proteins; 1998 May; 31(2):128-38. PubMed ID: 9593187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells.
    Hernández T; de Acosta CM; López-Requena A; Moreno E; Alonso R; Fernández-Marrero Y; Pérez R
    Mol Immunol; 2010; 48(1-3):98-108. PubMed ID: 20952071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional structure of an Fv from a human IgM immunoglobulin.
    Fan ZC; Shan L; Guddat LW; He XM; Gray WR; Raison RL; Edmundson AB
    J Mol Biol; 1992 Nov; 228(1):188-207. PubMed ID: 1447781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of long CDR3s into V domains: implications for the structural evolution of the antibody-combining site.
    Ramsland PA; Kaushik A; Marchalonis JJ; Edmundson AB
    Exp Clin Immunogenet; 2001; 18(4):176-98. PubMed ID: 11872949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain.
    Martin T; Crouzier R; Weber JC; Kipps TJ; Pasquali JL
    J Immunol; 1994 Jun; 152(12):5988-96. PubMed ID: 8207223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformations of the third hypervariable region in the VH domain of immunoglobulins.
    Morea V; Tramontano A; Rustici M; Chothia C; Lesk AM
    J Mol Biol; 1998 Jan; 275(2):269-94. PubMed ID: 9466909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of amino acid substitutions in the heavy chain CDR3 of an autoantibody on its reactivity.
    Adib-Conquy M; Gilbert M; Avrameas S
    Int Immunol; 1998 Mar; 10(3):341-6. PubMed ID: 9576622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.